



## I. Epidemiological profile

Population (UN Population Division)	2012	%
High transmission (>1 case per 1000 population)	5 980 000	100
Low transmission (0–1 cases per 1000 population)	0	0
Malaria-free (0 cases)	0	0
Total	5 980 000	

Parasites and vectors	
Major plasmodium species:	<i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)
Major anopheles species:	<i>An. gambiae</i> , <i>funestus</i> , <i>melas</i>
Programme phase: Control	

## II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Year adopted
<b>ITN</b>	ITNs/LLINs distributed free of charge	Yes	2010
	ITNs/LLINs distributed to all age groups	–	–
<b>IRS</b>	IRS is recommended	Yes	2005
	DDT is used for IRS	No	–
<b>Larval control</b>	Use of larval control	–	–
<b>IPT</b>	IPT used to prevent malaria during pregnancy	Yes	2005
<b>Diagnosis</b>	Patients of all ages should receive diagnostic test	Yes	2010
	Malaria diagnosis is free of charge in the public sector	Yes	2008
<b>Treatment</b>	ACT is free for all ages in public sector	Yes	2010
	Artemisinin-based monotherapies withdrawn	Yes	–
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for <i>P. falciparum</i>	–	–
	Primaquine is used for radical treatment of <i>P. vivax</i>	–	–
	G6PD test is a requirement before treatment with primaquine	–	–
	Directly observed treatment with primaquine is undertaken	–	–
	System for monitoring of adverse reaction to antimalarials exists	Yes	2005



Intervention	Policies/strategies	Yes/No	Year adopted
<b>Surveillance</b>	ACD for case investigation (reactive)	–	–
	ACD at community level of febrile cases (pro-active)	–	–
	Mass screening is undertaken	–	–
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	–	–
	Uncomplicated <i>P. vivax</i> cases routinely admitted	–	–

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	AS+AQ	2004
First-line treatment of <i>P. falciparum</i>	AL; AS+AQ	2004
For treatment failure of <i>P. falciparum</i>	QN	2004
Treatment of severe malaria	AM; QN	2004
Treatment of <i>P. vivax</i>	–	–
Dosage of primaquine for radical treatment of <i>P. vivax</i>	–	–



Type of RDT used	<i>Pf</i> only
Therapeutic efficacy tests (clinical and parasitological failure, %)	

Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
----------	------	-----	--------	-----	-----------	----------------	---------





## III. Financing



## IV. Coverage



## V. Impact



**Impact:** Insufficiently consistent data to assess trends